



HMNC Appoints New Chief Clinical Development Officer

February 1, 2021

HMNC Holding GmbH, a biopharma company focused on the development of innovative and personalized treatments for depression and anxiety disorders, announced today the appointment of Dr. Hans Eriksson as Chief Clinical Development Officer with effect of January 1, 2021. Dr. Eriksson will oversee the Research and Development of the HMNC Group. He will provide leadership and direction for the clinical program of the HMNC pipeline.

Dr. Eriksson brings in over 20 years of clinical development experience in academia and industry. He held several senior leadership positions at AstraZeneca, including Medical Science Director of Global Clinical Development. During his tenure at Lundbeck A/S, he was responsible for the clinical development program as Head of Depression and Pediatrics.

Before joining HMNC, Dr Eriksson was Chief Medical Officer of Compass Pathways, a Nasdaq-listed mental-health company.

“His clinical vision and proven leadership, as well as his extensive drug development experience will strengthen our clinical development efforts and support the progress of our product pipeline,” commented Dr. Franz Humer, Chairman of the Supervisory Board.

“I am excited about being a part of a dedicated team focused on developing innovative treatments for depression and look forward to advancing the company’s unique pipeline“, said Dr. Hans Eriksson

Dr. Eriksson received his M.D. and PhD in Cell and Molecular Biology from Lund University. Furthermore, he is a specialist in Psychiatry (The National Board of Health and Welfare) and holds an Executive MBA from Stockholm School of Economics.